AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00190606
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03381053
Drug: Imatinib 400mg
RxNorm normalized name: imatinib 400 MG
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The NIH assessment of patients with surgical excision of GIST with moderate to high risk of recurrence was recommended imatinib 400mg treatment.
Trial: NCT03380390
Drug: Oxymetazoline HCL 1.0% Cream
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxymetazoline HCl cream 1.0% once daily application
Trial: NCT03588715
Drug: Pegylated Interferon alpha 2b (peg-IFN-α2b)
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegylated Interferon alpha 2b (peg-IFN-α2b) will be administered weekly via subcutaneous route.
Trial: NCT03087578
Drug: Mirabegron 50 MG [Myrbetriq]
RxNorm normalized name: mirabegron 50 MG [Myrbetriq]
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 50 mg of mirabegron daily for 6 weeks.
Trial: NCT00877890
Drug: exenatide once weekly
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 2.0mg, once a week
Trial: NCT00877890
Drug: exenatide twice daily
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
Trial: NCT03071263
Drug: Patiromer
RxNorm normalized name: Patiromer
DrugBank: Patiromer (DB09263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 packets/day starting dose, administered orally
Trial: NCT01681836
Drug: 15Nitrogen(15N)-labeled sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrogen (DB09152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15Nitrogen(15N)-labeled sodium nitrite 20 mg once
Trial: NCT01681836
Drug: 15Nitrogen(15N)-labeled sodium nitrate
RxNorm normalized name: sodium nitrate 15N
DrugBank: Nitrogen (DB09152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15Nitrogen(15N)-labeled sodium nitrate 1,000 mg once
Trial: NCT01731756
Drug: Salicylic Acid (6%)
RxNorm normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
Trial: NCT01308528
Drug: Sodium enoxaparin
RxNorm normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/mL
Trial: NCT00510887
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle
Trial: NCT00510887
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 IV on day 1
Trial: NCT00510887
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25 mg/m2 IV on days 1,2,3
Trial: NCT00510887
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 10 mg/m2 IV on day 2
Trial: NCT01308528
Drug: Sodium Enoxaparin clexane
RxNorm normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clexane 40 mg/ 0,4 mL
Trial: NCT00510887
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 20 mg orally on days 1,2,3,4,5
Trial: NCT00466063
Drug: Deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04211740
Drug: OCH-NCNP1
RxNorm normalized name: NS 089/NCNP 02
DrugBank: Brogidirsen (DB18884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCH-NCNP1 3mg is supplied as granules and take orally once a week.
Trial: NCT02735044
Drug: Insulin glargine,300 U/mL
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter \[mmol/L\])
Trial: NCT02735044
Drug: Insulin glargine (100 units /mL)
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)
Trial: NCT00864123
Drug: D-cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (Seromycin, 250 mg; Eli Lilly and Co, Indianapolis, Indiana) will be capsulated into 25mg with identical placebo capsules. Children weighing between 25-45kg will be given a dosage of 25mg (approximately 0.56-1.0 mg/kg/day). Children weighing between 46-80kg will be given a dosage of 50mg (approximately 0.63-1.08mg/kg/day). DCS or placebo will be given by parents 1 hour prior to psychotherapy sessions (before sessions 4-10 only) based on past success in patients with acrophobia (Ressler et al., 2004) and DCS absorption rates.
Trial: NCT00386516
Drug: GM-CT-01
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression
Trial: NCT00386516
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression
Trial: NCT00314860
Drug: ropinirole Extended Release (XR)
RxNorm normalized name: ropinirole Extended Release Oral Tablet
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02655458
Drug: Elotuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The following must also be administered before any elotuzumab:~Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po).
Trial: NCT02655458
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.
Trial: NCT02481323
Drug: isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
Trial: NCT02481323
Drug: cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects
Trial: NCT02994576
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab, 1200 mg administered I.V. once
Trial: NCT02662972
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT01863823
Drug: Mouth washing
RxNorm normalized name: Zencia Wash
DrugBank: Sulfacetamide (DB00634)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two time washing mouth per day
Trial: NCT03841110
Drug: FT500
RxNorm normalized name: Fluticasone Propionate and Salmeterol Xinafoate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
Trial: NCT03841110
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immune Checkpoint Inhibitor
Trial: NCT00805649
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravitreal injection of 0.8 mg dexamethasone
Trial: NCT00805649
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal injection of 1.25 mg bevacizumab
Trial: NCT00805649
Drug: triamcincolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravitreal injection of 8 mg triamcincolone
Trial: NCT03841110
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immune Checkpoint Inhibitor
Trial: NCT03841110
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immune Checkpoint Inhibitor
Trial: NCT03841110
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lympho-conditioning agent
Trial: NCT03841110
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic response modifier
Trial: NCT04228263
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg
Trial: NCT04228263
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg
Trial: NCT01601535
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan will be administered intravenously during each course on study day 1 through day 5.
Trial: NCT01601535
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide will be administered orally during each course on study day 1 through day 5.
Trial: NCT00632216
Drug: Risedronate Sodium
RxNorm normalized name: Risedronate Sodium
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03084796
Drug: CHF 5259
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Response: Test one of four different doses of CHF 5259
Trial: NCT03084796
Drug: Tiotropium Bromide 18 µg Inhalation Capsule
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Control
Trial: NCT00647296
Drug: Dexpramipexole 50 mg/day
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexpramipexole: 2 x 12.5 mg tablets taken orally twice daily
Trial: NCT00647296
Drug: Dexpramipexole 150 mg/day
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexpramipexole: 2 x 37.5 mg tablets taken orally twice daily
Trial: NCT00647296
Drug: Dexpramipexole 300 mg/day
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexpramipexole: 2 x 75 mg tablets taken orally twice daily
Trial: NCT00153296
Drug: Carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00416208
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
Trial: NCT00912639
Drug: Paclitaxel loaded Polymeric micelle
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Genexol-PM at a dose of 300mg/m2 was diluted in 500 ml of 5% dextrose solution or normal saline and infused i.v. for 3 h on day 1.Treatment was repeated every 3 weeks until either disease progression or intolerance. A minimum of 6 cycles was recommended.
Trial: NCT03013426
Drug: NVX-508
RxNorm normalized name: NVX-CoV2373
DrugBank: Nuvaxovid (DB15810)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of NVX-508 emulsion intravenously
Trial: NCT02531633
Drug: Sirukumab
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
Trial: NCT04520607
Drug: Lorecivivint
RxNorm normalized name: Lorecivivint
DrugBank: Lorecivivint (DB14883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthcare professional-administered intra-articular injections of lorecivivint.
Trial: NCT02531633
Drug: Placebo to match sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
Trial: NCT02531633
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
Trial: NCT02531633
Drug: Placebo to match prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo to match prednisone will be provided as tablets.
Trial: NCT00364611
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on~* On Day 1 of the 1st cycle over 120 minutes~* On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose~* On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses~* On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses
Trial: NCT00225901
Drug: Recombinant human hepatocyte growth factor
RxNorm normalized name: Recombinant human insulin-like growth factor 1
DrugBank: Recombinant human insulin-like growth factor 1 (DB18684)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00364611
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m\^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
Trial: NCT00232063
Drug: ciclosporin
RxNorm normalized name: Ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01992588
Drug: Faster-acting insulin aspart
RxNorm normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump.
Trial: NCT04711213
Drug: Dexamethasone Dose 1
RxNorm normalized name: dexamethasone Metered Dose Inhaler
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone ophthalmic suspension dose 1
Trial: NCT04711213
Drug: Dexamethasone Dose 2
RxNorm normalized name: dexamethasone 2 MG
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone ophthalmic suspension dose 2
Trial: NCT01992588
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump.
Trial: NCT00871910
Drug: SCH 727965
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)
Trial: NCT00871910
Drug: SCH 727965
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts
Trial: NCT00871910
Drug: SCH 727965
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts
Trial: NCT00871910
Drug: SCH 727965
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle
Trial: NCT00871910
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.
Trial: NCT00871910
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.
Trial: NCT00871910
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.
Trial: NCT00364611
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.~* For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion
Trial: NCT00171067
Drug: valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00171067
Drug: lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01238705
Drug: Felodipine add Irbesartan
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Irbesartan,150mg/day, Sanofi - Aventis Pharmaceutical company, Registration Number: H20080074.
Trial: NCT01238705
Drug: Felodipine add Metoprolol
RxNorm normalized name: felodipine / metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Metoprolol Succinate,47.5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: J20050061.
Trial: NCT03425734
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
Trial: NCT04111328
Drug: intravenous hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The PCA pumps contain hydromorphone. And the pump is connected to participants intravenously .
Trial: NCT04111328
Drug: subcutaneous hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The PCA pumps contain hydromorphone. And the pump is connected to participants subcutaneously.
Trial: NCT04111328
Drug: intravenous hydromorphone and dexmedetomidine
RxNorm normalized name: hydromorphone and antispasmodics
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants intravenously.
Trial: NCT04111328
Drug: subcutaneous hydromorphone and dexmedetomidine
RxNorm normalized name: hydromorphone and antispasmodics
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants subcutaneously
Trial: NCT01080625
Drug: phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
Trial: NCT00057265
Drug: telbivudine or lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00470873
Drug: Levitra (Vardenafil, BAY38-9456)
RxNorm normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
Trial: NCT02368730
Drug: desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes